Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Arcutis Biotherapeutics Inc FDA Approval Conference Call Transcript

Aug 01, 2022 / 12:30PM GMT
Release Date Price: $20.26 (-16.49%)
Operator

Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics FDA Approval Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Mr. Eric McIntyre, Head of Investor Relations. Mr. McIntyre. Please go ahead.

Eric McIntyre
Arcutis Biotherapeutics, Inc. - Head of IR

Thank you, Chris. Good morning, everyone, and thank you for joining. As you can imagine, we're all incredibly proud and excited to be here with you this morning to discuss the FDA approval of ZORYVE for plaque psoriasis.

Just a couple of logistical details before we get started. Today's webcast and posted presentation can be found under the Events and Presentations tab of our Investors section of our website. And then just a reminder to everyone that the safe harbor rules govern our remarks today and as well as any forward-looking statements that we may make during this call. These statements are subject to any risks and uncertainties that could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot